Executive Summary
Curis, Inc.-Product Pipeline Review-2015
Summary
Global Markets Direct's, 'Curis, Inc.-Product Pipeline Review-2015', provides an overview of the Curis, Inc.'s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Curis, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides brief overview of Curis, Inc. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Curis, Inc.'s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the Curis, Inc.'s pipeline products
Reasons To Buy
Evaluate Curis, Inc.'s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Curis, Inc. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Curis, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Curis, Inc. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Curis, Inc.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Curis, Inc. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues
Read More
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Curis, Inc. Snapshot 5
Curis, Inc. Overview 5
Key Information 5
Key Facts 5
Curis, Inc.-Research and Development Overview 6
Key Therapeutic Areas 6
Curis, Inc.-Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products-Monotherapy 9
Pipeline Products-Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Curis, Inc.-Pipeline Products Glance 12
Curis, Inc.-Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Curis, Inc.-Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Curis, Inc.-Drug Profiles 14
CUDC-101 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CUDC-427 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CUDC-907 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CUDC-906 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CUDC-908 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Curis, Inc.-Pipeline Analysis 21
Curis, Inc.-Pipeline Products by Target 21
Curis, Inc.-Pipeline Products by Route of Administration 22
Curis, Inc.-Pipeline Products by Molecule Type 23
Curis, Inc.-Pipeline Products by Mechanism of Action 24
Curis, Inc.-Recent Pipeline Updates 25
Curis, Inc.-Dormant Projects 31
Curis, Inc.-Discontinued Pipeline Products 32
Discontinued Pipeline Product Profiles 32
CUDC-305 32
Curis, Inc.-Company Statement 33
Curis, Inc.-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38
List of Figures
Curis, Inc.-Pipeline by Top 10 Indication, 2015 6
Curis, Inc.-Pipeline by Stage of Development, 2015 8
Curis, Inc.-Monotherapy Products in Pipeline, 2015 9
Curis, Inc.-Partnered Products in Pipeline, 2015 10
Curis, Inc.-Pipeline by Top 10 Target, 2015 21
Curis, Inc.-Pipeline by Top 10 Route of Administration, 2015 22
Curis, Inc.-Pipeline by Top 10 Molecule Type, 2015 23
Curis, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 24
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Current R&D Portfolio of Curis, Inc.; Curis, Inc. - Key Therapeutics; Curis, Inc. - Pipeline Overview and Promising Molecules; Curis, Inc. - News; Curis, Inc. - Latest Updates; Curis, Inc. - Pipeline; Curis, Inc. - Discontinued/Dormant Projects
|
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
